Erschienen in:
18.04.2017 | Research Letter
Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series
verfasst von:
Nino Cristiano Chilelli, Giuseppe Bax, Giulio Bonaldo, Eugenio Ragazzi, Massimo Iafrate, Filiberto Zattoni, Federico Bellavere, Annunziata Lapolla
Erschienen in:
Endocrine
|
Ausgabe 3/2018
Einloggen, um Zugang zu erhalten
Excerpt
As outlined in the latest recommendations for patients with type 2 diabetes (DM2), sodium glucose cotransporter 2 inhibitors (SGLT2i) can be added on treatments with metformin or sulfonylurea plus metformin if glycemic goals are not met [
1]. Genital and urinary infections are well-known side effects of SGLT2i, with reported odds ratios in the range of 3.21–5.23, compared with placebo [
2,
3]. …